Ventracor Limited Chief Executive Officer Colin Sutton PhD said: "Clinical knowledge and experience in surgical procedures and patient management is growing rapidly.
"Recent implants in Norway, Perth, Sydney, Auckland and Brisbane bring enrolments in the CE Mark Trial closer to completion.
"We expect there will be additional implants in the coming weeks and are on track to complete recruitment in the CE Mark Trial before the end of the first quarter 2006."
Dr Sutton added Ventracor had developed training programs and added field support which would allow the company to carefully expand the number of European hospitals implanting the VentrAssist LVAD.
Ventracor's CE Mark Trial is aimed at obtaining approval to sell the VentrAssist
Dr Sutton added Ventracor continued to focus on achieving key milestones.
Ventracor is a global medical device company that has developed a blood pump, the VentrAssist
For further information, please contact:
Manager, Investor Relations